Device Trial Radar · NCT05565443
MR-guided Focused Ultrasound Plus GCase
Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
14
Planned (sponsor's estimate)
Start
Nov 30, 2022
Primary completion
Nov 1, 2026
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- InSightecNot on our public-company list
- Sponsor type
- Industry
- First posted
- Oct 4, 2022
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 35 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this study is to establish safety and feasibility of intracerebral delivery of GCase via MRgFUS. This technique may offer potential benefits given the exposure of the putamen to GCase in animal models has been shown to be efficacious in improving Parkinson's disease pathology and phenotype.
Conditions
- Parkinsons Disease
Interventions
Blood Brain Barrier Disruption - FunctionalDevice
Delivery of GCase across the BBB to form a disease modifying strategy for patients with Parkinson's Disease
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse EventsTime frame: 12 Months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sunybrook Research Institute
Toronto, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.